Krakow, Poland, 27 August 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, will publish the most recent data from its oncology programs at the 6th Annual Immuno-Oncology Summit, which is taking place on August 27 – 31 2018, in Boston, MA, USA.
Data presented at the conference will include recent results from Selvita’s discovery phase project targeting cancer immunometabolism – dual A2A/A2B adenosine receptor antagonists, as well as cancer immunotherapy – novel class of small molecule direct STING agonists.
“We are delighted to be able to present new results from our early discovery projects. We see our immunometabolism and immunooncology programs as important and very promising assets in Selvita’s pipeline”, said Krzysztof Brzozka, Chief Scientific Officer at Selvita. – “We are fighting for a better future of many oncology patients and we believe that every day we are getting closer to that goal.”
The results from Selvita research and development programs will be presented for 5 days of the conference:
- The poster presentation entitled: “Novel class of small molecule direct STING agonists as potential cancer immunotherapy”, Abstract no. 36.
- The poster presentation entitled: “Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”, Abstract no. 37.
Selvita Oncology Pipeline
In its internal research and development efforts, Selvita focuses on different dimensions of oncology. The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, licensed to Menarini Group. The second most advanced program is SEL120, the first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer, currently in IND-enabling studies. In August 2017 Selvita signed a partnering agreement with The Leukemia and Lymphoma Society for preclinical and Phase I clinical development of SEL120 in area of AML, within the Therapy Acceleration Program. Selvita Early Discovery Programs are focused on a number of novel oncology targets in the area of kinase inhibitors, cancer metabolism & immunometabolism and immunooncology.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).